Skip to main content

Advertisement

Table 3 Characteristics of children who did and did not develop tuberculosis (TB) following co-trimoxazole randomization

From: Tuberculosis incidence is high in HIV-infected African children but is reduced by co-trimoxazole and time on antiretroviral therapy

At co-trimoxazole randomization TB No TB Total P value
  20 (3 %) 602 (97 %) 622  
Randomization
 Stop co-trimoxazole 15 (5) 297 (95) 312  
 Continue co-trimoxazole 5 (2) 305 (98) 310 0.024
Age (at co-trimoxazole randomization)
 Median, IQR 6.5 (3.5–11.5) 7 (4–10)   
 <5 years 10 (3) 280 (97) 290 0.75
Sex
 Male 8 (3) 295 (97) 303  
 Female 12 (4) 307 (96) 319 0.43
CD4 median IQR (time-updated)
 CD4 % 18 (11.5–31) 33 (26–38)   <0.001
Weight median IQR (time-updated)
 Weight-for-age Z score −1.0 (−2.1 to –0.5) −1.3 (1.9 to –0.6)   0.60
Height median IQR (time-updated)
 Height-for-age Z score −1.8 (−3.0 to –0.9) −1.9 (−2.7 to –1.1)   0.92
WHO stage (pre-ART)
 3 and 4 13 (3) 378 (97) 391 0.84
ART randomization
 A (3TC/ABC/NNRTI throughout) 8 (4) 192 (96) 200  
 B (3TC/ABC/NNRTI post week 36) 8 (4) 210 (96) 218  
 C (3TC/ABC/ZDV post week 36) 4 (2) 200 (98) 204 0.46
ART at co-trimoxazole randomization
 3TC ABC EFV 4 (3) 134 (97) 138  
 3TC ABC NVP 11 (4) 245 (96) 256  
 ZDV 3TC ABC 4 (2) 196 (98) 200  
 Other 1 (4) 27 (96) 28 0.58
  1. Values are n (row%) unless otherwise stated
  2. 3TC Lamivudine, ABC Abacavir, ART Antiretroviral therapy, EFV Efavirenz, IQR Interquartile range, NNRTI Non-nucleoside reverse transcriptase inhibitor, NVP Nevirapine, ZDV Zidovudine